# Venetoclax Plus Inotuzumab for B-ALL

> **NCT05016947** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 23 (actual)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- B-Cell Lymphoma
- ALL

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone
- **DRUG:** Inotuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT05016947
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-24
- **Primary completion:** 2023-07-10
- **Final completion:** 2026-12-23
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05016947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05016947, "Venetoclax Plus Inotuzumab for B-ALL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05016947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*